Primary hyperparathyroidism - Is mild disease worth treating?

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 10, Issue 1, 2010, Pages 45-49

  Gittoes, N J L ^a   Cooper, M S ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Hypercalcaemia; Parathyroidectomy; Primary hyperparathyroidism

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM ION; CINACALCET; CREATININE;

ARTERIAL STIFFNESS; BONE DENSITY; BONE DISEASE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CANCER RISK; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CONFERENCE PAPER; CONSERVATIVE TREATMENT; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; HYPERTENSION; LIFE EXPECTANCY; NEPHROLITHIASIS; PARATHYROIDECTOMY; PRIMARY HYPERPARATHYROIDISM; RISK REDUCTION; SECONDARY HYPERPARATHYROIDISM; VASCULAR RESISTANCE;

EID: 77149136083     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.10-1-45     Document Type: Conference Paper

References (36)

1. Silverberg SJ, Shane E, Jacobs TP et al. Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med 1990;89:327-34.
2. Udelsman R. Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Ann Surg 2002;235:665-70.
3. Udelsman R, Pasieka JL, Sturgeon C, Young JE, Clark OH. Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009;94:366-72.
4. Mollerup CL, Vestergaard P, Frokjaer VG et al. Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. BMJ 2002;325:807.
5. Vestergaard P,Mollerup CL, Frokjaer VG et al. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 2000;321:598-602.
6. Bilezikian JP, Potts JT, Jr, Fuleihan G et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002;87:5353-61.
7. Bilezikian JP, Khan AA, Potts JT, Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009;94:335-9.
8. Rubin MR, Bilezikian JP, McMahon DJ et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008;93:3462-70.
9. Rao DS, Phillips ER, Divine GW, Talpos GB. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2004;89:5415-22.
10. Bollerslev J, Jansson S,Mollerup CL et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 2007;92:1687-92.
11. Ambrogini E, Cetani F, Cianferotti L et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 2007;92:3114-21.
12. Stefenelli T, Mayr H, Bergler-Klein J et al. Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am J Med 1993;95:197-202.
13. Hedback G, Oden A, Tisell LE. The influence of surgery on the risk of death in patients with primary hyperparathyroidism.World J Surg 1991;15:399-405.
14. Wermers RA, Khosla S, Atkinson EJ et al. Survival after the diagnosis of hyperparathyroidism: a population-based study. Am J Med 1998;104:115-22.
15. Hedback GM, Oden AS. Cardiovascular disease, hypertension and renal function in primary hyperparathyroidism. J Intern Med 2002;251:476-83.
16. Lind L, Jacobsson S, Palmer M et al. Cardiovascular risk factors in primary hyperparathyroidism: a 15-year follow-up of operated and unoperated cases. J Intern Med 1991;230:29-35.
17. Lind L, Skarfors E, Berglund L, Lithell H, Ljunghall S. Serum calcium: a new, independent, prospective risk factor for myocardial infarction in middle-aged men followed for 18 years. J Clin Epidemiol 1997;50:967-73.
18. Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone levels predict coronary heart disease: the Tromso Study. Eur J Cardiovasc Prev Rehabil 2004;11:69-74.
19. Nilsson IL, Aberg J, Rastad J, Lind L. Maintained normalization of cardiovascular dysfunction 5 years after parathyroidectomy in primary hyperparathyroidism. Surgery 2005;137:632-8.
20. Piovesan A, Molineri N, Casasso F et al. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf) 1999;50:321-8.
21. Almqvist EG, Bondeson AG, Bondeson L et al. Cardiac dysfunction in mild primary hyperparathyroidism assessed by radionuclide angiography and echocardiography before and after parathyroidectomy. Surgery 2002;132:1126-32.
22. Nilsson IL, Aberg J, Rastad J, Lind L. Left ventricular systolic and diastolic function and exercise testing in primary hyperparathyroidism-effects of parathyroidectomy. Surgery 2000;128:895-902.
23. Rubin MR, Maurer MS, McMahon DJ, Bilezikian JP, Silverberg SJ. Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2005;90:3326-30.
24. Wajngot A,Werner S, Granberg PO, Lindvall N. Occurrence of pituitary adenomas and other neoplastic diseases in primary hyperparathyroidism. Surg Gynecol Obstet 1980;151:401-3.
25. Farr HW, Fahey TJ, Jr, Nash AG, Farr CM. Primary hyperparathyroidism and cancer. Am J Surg 1973;126:539-43.
26. Rossini M, Gatti D, Isaia G et al. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 2001;16:113-9.
27. Chow CC, Chan WB, Li JK et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:581-7.
28. Khan AA, Bilezikian JP, Kung AW et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004;89:3319-25.
29. Diamond T, Ng AT, Levy S, Magarey C, Smart R. Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: a preliminary report. Osteoporos Int 1996;6:329-33.
30. Guo CY, Thomas WE, al-Dehaimi AW, Assiri AM, Eastell R. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 1996;81:3487-91.
31. Peacock M, Bilezikian JP, Klassen PS et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005;90:135-41.
32. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25.
33. Khan A, Grey A, Shoback D. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009;94:373-81.
34. Sejean K, Calmus S, Durand-Zaleski I et al. Surgery versus medical follow-up in patients with asymptomatic primary hyperparathyroidism: a decision analysis. Eur J Endocrinol 2005;153:915-27.
35. Zanocco K, Angelos P, Sturgeon C. Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism. Surgery 2006;140:874-81.
36. Zanocco K, Sturgeon C. How should age at diagnosis impact treatment strategy in asymptomatic primary hyperparathyroidism? A cost-effectiveness analysis. Surgery 2008;144:290-8.